Dilution profile // every instrument, one screen, from SEC filings

Rapport Therapeutics, Inc. (RAPP)

CIK 2012593 · all EDGAR filings →

Overall dilution risk
HIGHworst of 3 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGH$150M registered
= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)
one or more live registrations had no structured fee data, so the true total is AT LEAST this
Overhead supply
NOT COMPUTEDno warrant count tagged in XBRL
= warrant shares outstanding divided by current shares outstanding
absence of a tag is not proof of absence of warrants
Historical dilution
MEDIUM+31% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
LOW~59.8 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2024-08-082026-08-03

Latest: 48.0M shares as of Aug 3, 2026 (10-Q).

Cash runway

Self-funding

generates cash

Full breakdown: cash runway tool · source filing →

Warrants

No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 5, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Registrations and offerings

Registered offering capacity on live registrations: $150.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-3ASRMar 10, 2026$150.0M registeredfiling →
S-3Jul 1, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-3Jul 1, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 3 executed · 1 registered.

REGISTEREDMar 10, 2026Automatic shelf registration — effective immediately (large filers)S-3ASR
EXECUTEDJan 7, 2026Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDSep 10, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDSep 8, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEJul 9, 2025SEC declared a registration effective — selling can beginEFFECT
EFFECTIVEJul 9, 2025SEC declared a registration effective — selling can beginEFFECT
REGISTEREDJul 1, 2025S-3 registration — capacity to sell shares, not a sale yetS-3
REGISTEREDJul 1, 2025S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDJun 10, 2024Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJun 7, 2024Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4
EFFECTIVEJun 6, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDJun 3, 2024S-1/A registration — capacity to sell shares, not a sale yetS-1/A

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full RAPP workspace